Metabolomic Analysis of Systemic Sclerosis
Key facts
- Where
- Dijon, Metz, Reims és Strasbourg, FranciaországSee the 4 sites
Where in Franciaország
- CHUDijon, FranciaországNo longer taking part
- Hopitaux Prives De MetzMetz, FranciaországNo longer taking part
- CHUReims, FranciaországNo longer taking part
- Hopitaux Universitaires de StrasbourgStrasbourg, FranciaországNo longer taking part
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT02298777
- Record updated
- 2025. augusztus 8.
- Original description
Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.Read full original descriptionShow less
Currently investigators do not have diagnostic and prognostic markers for SSc which almost always starts with a vascular disease (Raynaud's disease) isolated for several years.
The primary purpose is to highlight discriminating metabolic profiles depending on the characteristics of the disease, allowing early diagnosis of SSc at the onset of vascular lesions, by comparing the profiles of SSc beginners (<3 years) to established forms (> 3 years).
Secondary purposes:
* Prognosis: to study the metabolomics profile of SSc when a visceral complication occurs * Diagnosis: to compare the metabolomics profile of SSc to undifferentiated connective tissue disease (UCDT), Raynaud's disease (RD), vascular disease (VD) and healthy controls * Exploratory: to compare the metabolomics profile of blood, urine and skin of SSc patients
Inclusion: Group 1 (scleroderma) : Patients with ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001); Group 2 (UCDT) : Patients with criteria proposed by Mosca et al. (1998); Group 3 (Raynaud) : Patients with primary and isolated Raynaud disease; Group 4 (vascular disease) : Patients with type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke; Group 5 (healthy control) : healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease).
Exclusion: Group 1 (scleroderma) : Patients not fulfilling ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001), or with another auto-immune disease; Group 3 (Raynaud) : Patients with no Raynaud disease; Group 4 (vascular disease) : Patients with no vascular disease; Group 5 (healthy control) : Patients with sign of connective tissue disease, Raynaud, or vascular disease); Group 2 (UCDT) : Patients not fulfilling criteria proposed by Mosca et al. (1998).